13 completed, 1 terminated. 14 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 13, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow pasireotide: new trials by email Literature Review of pasireotide trials Research Report on pasireotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 HTL0030310, Pasireotide, Placebo - Healthy | Phase 1 | Completed | Nxera Pharma UK Limited | 42 | 2019-01-23 | 2025-02-19 |
| Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia Pasireotide - Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia | Phase 1 | Completed | University of Colorado, Denver | 1 | 2017-03-22 | 2021-09-29 |
| Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer SOM230 - Castration Resistant Prostate Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 9 | 2013-03-08 | 2020-12-21 |
| Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs RAD001, SOM230 - Neuroendocrine Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 18 | 2012-05-18 | 2019-04-16 |
| A Phase l Study to Evaluate the Pharmacokinetics and Safety Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Volunteers SOM230 - Renal Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 50 | 2012-05-01 | 2020-12-21 |
| Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases Pasireotide, Sir-sphere Radioembolization, Everolimus - Neuroendocrine Tumors | Phase 1 | Completed | Emory University | 13 | 2011-12-01 | 2018-10-18 |
| Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer docetaxel, pasireotide, prednisone - Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 18 | 2011-10-01 | 2021-03-25 |
| Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) Pasireotide LAR - Neuroendocrine Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 29 | 2011-08-01 | 2020-12-21 |
| Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor SOM 230 / Pasireotide - Ductal Carcinoma in Situ | Phase 1 / Phase 2 | Terminated | NYU Langone Health | 9 | 2011-06-01 | 2017-12-27 |
| SOM 230 and Gemcitabine in Advanced Pancreatic Cancer SOM 230 LAR, Gemcitabine - Pancreatic Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2011-06-01 | 2020-09-28 |
| Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors SOM230, RAD001 - Neuroendocrine Tumor, Carcinoid Tumor | Phase 1 | Completed | Dana-Farber Cancer Institute | 22 | 2008-10-01 | 2016-10-19 |
| Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function Pasireotide - Hepatic Cirrhosis, Alcoholism | Phase 1 | Completed | Novartis Pharmaceuticals | 34 | 2008-07-01 | 2020-12-21 |
| Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial SOM 230 / Pasireotide - Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS) | Phase 1 | Completed | NYU Langone Health | 15 | 2007-11-01 | 2016-12-05 |
| Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease Pasireotide - Carcinoid Tumor, Acromegaly | Phase 1 | Completed | Novartis Pharmaceuticals | 85 | 2006-06-01 | 2020-12-21 |
Neuroendocrine Tumors (4) · Carcinoid Tumor (2) · Carcinoma, Intraductal, Noninfiltrating (2) · Prostatic Neoplasms (2) · Acromegaly (1) · Adenocarcinoma (1) · Adenoma, Islet Cell (1) · Alcoholism (1) · Breast Carcinoma In Situ (1) · Congenital Hyperinsulinism (1) · Liver Cirrhosis (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Renal Insufficiency (1)
Novartis Pharmaceuticals (6) · NYU Langone Health (2) · Barbara Ann Karmanos Cancer Institute (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Nxera Pharma UK Limited (1) · University of Colorado, Denver (1)
United States (10) · Germany (5) · Belgium (2) · South Africa (2) · Canada (1) · Netherlands (1) · Norway (1) · United Kingdom (1)
David L Kleinberg, MD (2) · Bassel El-Rayes, MD (1) · Deborah Axelrod, MD (1) · Helen Lawler, MD (1) · Jennifer Ang Chan, MD, MPH (1) · Julia Smith, MD (1) · Mike McDermott, MD (1) · Philip Evans, MBChB (1) · Richard Kim, M.D. (1) · Ulka Vaishampayan (1)
PMID 22282526, PMID 22736724, PMID 24800725, PMID 25385439, PMID 26126727, PMID 28721067, PMID 29451701
2005 (1), 2018 (1)